Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

NCT05097209 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Camrelizumab
DRUG: Gemcitabine
DRUG: Induction Cisplatin
RADIATION: intensity-modulated radiotherapy
DRUG: Concurrent cisplatin

Sponsor

Wei Jiang

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]